cannabidiol vs tacrolimus topical
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of cannabidiol and tacrolimus topical. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
( 2.4 , 5.10 , 7.2 ) Therapeutic drug monitoring and dose reduction for tacrolimus extended-release capsules should be considered when tacrolimus extended-release capsules is co-administered with cannabidiol. 7.3 Cannabidiol The blood levels of tacrolimus may increase upon concomitant use with cannabidiol. When cannabidiol and tacrolimus extended-release capsules are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity.
Epidiolex
Protopic
Epidiolex is a medicine that contains cannabidiol. It is used to treat seizures in people with certain conditions.
Tacrolimus extended-release capsules help prevent organ rejection in kidney transplant patients. It works by suppressing your immune system.
Epidiolex is used to treat seizures linked to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC). It is for patients who are at least 1 year old. These conditions can cause seizures that are hard to control.
This medicine is used to prevent your body from rejecting a new kidney after a transplant. It is for adult patients who can swallow capsules whole. You will take it with other medicines that also suppress your immune system.
Epidiolex contains cannabidiol, which is a substance that may affect how the brain works. It is thought to reduce seizures by acting on certain brain chemicals. The exact way it works is not fully understood.
Tacrolimus belongs to a class of drugs called calcineurin inhibitors. It lowers the activity of your immune system. This helps prevent your body from attacking your new kidney.
- • Feeling sleepy
- • Decreased appetite
- • Diarrhea
- • Changes in liver blood tests
- • Feeling tired or weak
- • Diarrhea
- • Constipation
- • Nausea
- • Swelling in your arms and legs
- • Tremors
- Seizure 5,791
- Hospitalisation 2,073
- Diarrhoea 1,695
- Somnolence 1,242
- Death 1,204
No adverse event reports.
Epidiolex can cause liver problems. Your doctor will check your liver before you start and during treatment. Tell your doctor right away if you feel very tired, have yellowing of the skin or eyes, dark urine, or loss of appetite. Epidiolex may also cause sleepiness or suicidal thoughts. Tell your doctor if you have any changes in mood or behavior.
This medicine can increase your risk of serious infections and certain cancers. These problems could lead to hospitalization or even death. This drug is not approved for liver transplants and may increase the risk of death in female liver transplant patients.
Tell your doctor if you are pregnant or plan to become pregnant. Epidiolex may harm your unborn baby. There are pregnancy programs to monitor outcomes, so talk to your doctor about enrolling. It is not known if Epidiolex passes into breast milk, so talk to your doctor about the best way to feed your baby if you are taking this medicine.
Tacrolimus can harm your unborn baby. Tell your doctor right away if you are pregnant or plan to become pregnant. There is a pregnancy registry to track outcomes in women who take tacrolimus during pregnancy.
Also Compare, Nearby Drugs
Compare tacrolimus topical with
How to Read This cannabidiol vs tacrolimus topical Comparison
cannabidiol is classified in the Cannabinoid (Anticonvulsant) drug class, while tacrolimus topical sits within the Calcineurin Inhibitor (Topical) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cannabidiol has 12,005 submissions while tacrolimus topical has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to cannabidiol slows down the process of clearing tacrolimus from your body, which can cause the drug to reach high and potentially harmful levels.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cannabidiol or tacrolimus topical.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.